Horizon Scanning

It is a challenge for health plans and clinicians to know what emerging technologies are in the preapproval phase and what their clinical, financial, and risk impacts might be. This is where we come in.

The Hayes Horizon Scanning Solution identifies innovative and potentially disruptive health technologies that are in various stages of the regulatory approval process. Our Research Analysts continually investigate new technologies that are on the horizon or in the early stages of clinical investigation, as well as the testing of existing technologies that may be seeking approval for new clinical applications. Hayes Horizon Scanning helps you track emerging technologies before you need to make decisions. Accessed through the Hayes Knowledge Center, Hayes Horizon Scanning addresses the following fundamental questions to help our clients forecast emerging technologies:

  • Is this emerging technology new or replacing an existing technology?
  • Where is this technology in the FDA regulatory process?
  • When will this technology be commercially available in the market?
  • What is the projected use, cost, and financial impact of this technology?

Selenia® Dimensions® Digital Tomosynthesis System

A three-dimensional breast imaging system that uses a rotating x-ray tube to acquire multiple images of the breast from several angles, intended for use as an adjunct or replacement for screen-film and digital mammography.

Linzess™ (Linaclotide)

A once-daily oral treatment for irritable bowel syndrome with constipation, as well as chronic constipation.

Bapineuzumab (AAB-001)

An intravenous passive immunotherapy for the treatment of patients with mild to moderate Alzheimer’s disease.

CorPath® 200 System

A robotic-assisted system for guiding percutaneous coronary intervention procedures used in conjunction with an interventional fluoroscopic imaging system, intended to reduce operator radiation exposure and procedure-related fatigue.

Kyprolis™ (Carfilzomib)

An intravenous, next-generation proteasome inhibitor for third-line treatment of multiple myeloma.

Resolute Integrity™ Zotarolimus-Eluting Coronary Stent

A zotarolimus-eluting stent coated with BioLinx, a biocompatible proprietary polymer blend with hydrophilic and noninflammatory properties, designed to extend the delivery time of zotarolimus to the vessel wall to treat complex lesions that may have delayed healing time and greater prolonged risk for restenosis.

IMT™ (Implantable Miniature Telescope)

An intraocular implant that provides visual magnification to patients with moderate to profound central vision impairment due to advanced age-related macular degeneration.